Home > Research & Development > References

printbutton

References 

 
(1) Research on Adverse Drug Events. I. Muscarinic M3 Receptor Binding Affinity Could Predict the Risk of Antipsychotics to Induce Type 2 Diabetes. Silvestre JS, Prous J. Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):289-304.    
 
(2) Toxicological and Clinical Computational Analysis by the Informatics and Computational Safety Analysis Staff of the US FDA/CDER. Daniel R. Benz, Edwin J. Matthews, Naomi L. Kruhlak, Anna A. Frid, Barbara L. Minnier and Joseph F. Contrera. AATEX 14, Special Issue, 463-467, Proc. 6th World Congress on Alternatives & Animal Use in the Life Sciences, August 21-25, 2007, Tokyo, Japan. 
  
(3) Comparative evaluation of hERG potassium channel blockade by antipsychotics. Silvestre JS, Prous JR. Methods Find Exp Clin Pharmacol. 2007 Sep;29(7):457-65.    ...view article abstract
 
(4) Combined Use of MC4PC, MDL-QSAR, BioEpisteme, Leadscope PDM, and Derek for Windows Software to Achieve High-Performance, High-Confidence Mode of Action-Based Predictions of Chemical Carcinogenesis in Rodents. Edwin J. Matthews;  Naomi L. Kruhlak;  R. Daniel Benz;  Joseph F. Contrera;  Carol A. Marchant; Chihae Yang. Toxicology Mechanisms and Methods, Volume 18, Issue 2 & 3 February 2008, pages 189 - 206  ...view article abstract
 
(5) Identification of Structure Activity Relationships for Adverse Effects of Pharmaceuticals in Humans: B: Use of (Q)SAR Systems for Early Detection of Drug-Induced Urinary Tract and Hepatobiliary Toxicities. Matthews, E. J., Ursem, C. J., Kruhlak, N. L., Benz, R. D., Aragonés Sabaté, D., Prous, J. R., Yang, C., Klopman, G., and Contrera, J. F. 30 January 2009. Regul. Toxicol. Pharmacol.    ...view article abstract
  
(6) Identification of structure–activity relationships for adverse effects of pharmaceuticals in humans: Part C: Use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities. Matthews EJ, Kruhlak NL, Benz RD, Aragonés Sabaté D, Marchant CA, Contrera JF.Regul Toxicol Pharmacol. 2009 Jun;54(1):43-65
...view article abstract